Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4854179
Max Phase: Preclinical
Molecular Formula: C53H71F12N13O15
Molecular Weight: 902.11
Molecule Type: Unknown
Associated Items:
ID: ALA4854179
Max Phase: Preclinical
Molecular Formula: C53H71F12N13O15
Molecular Weight: 902.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(C(=O)CCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C45H67N13O7.4C2HF3O2/c1-30(41(62)54-44(65)36(11-7-19-46)52-31(2)59)51-43(64)35(12-8-20-50-45(47)48)49-21-24-55-25-27-57(28-26-55)39(60)16-15-32-17-22-56(23-18-32)29-40(61)58-37-13-5-3-9-33(37)42(63)53-34-10-4-6-14-38(34)58;4*3-2(4,5)1(6)7/h3-6,9-10,13-14,30,32,35-36,49H,7-8,11-12,15-29,46H2,1-2H3,(H,51,64)(H,52,59)(H,53,63)(H4,47,48,50)(H,54,62,65);4*(H,6,7)/t30-,35-,36-;;;;/m0..../s1
Standard InChI Key: XVNUADDOCGTDHD-SIDQARSZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 902.11 | Molecular Weight (Monoisotopic): 901.5286 | AlogP: 0.17 | #Rotatable Bonds: 21 |
Polar Surface Area: 280.52 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 11.98 | CX LogP: -2.64 | CX LogD: -7.04 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.05 | Np Likeness Score: -0.45 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):